Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Conduit C, Davis ID, Goh JC, Kichenadasse G, Gurney H, Harris CA, Pook D, Krieger L, Parnis F, Underhill C, Adams D, Roncolato F, Joshua A, Ferguson T, Prithviraj P, Morris M, Harrison M, Begbie S, Hovey E, George M, Liow EC, Link EK, McJannett M, Gedye C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); UNISoN Investigators. Conduit C, et al. Among authors: liow ec. BJU Int. 2024 Feb;133 Suppl 3:57-67. doi: 10.1111/bju.16190. Epub 2023 Nov 20. BJU Int. 2024. PMID: 37986556 Clinical Trial.
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
Moe A, Liow E, Redfern A, Swarbrick N, Ferguson T, Davis ID, Hayne D. Moe A, et al. BJU Int. 2021 Oct;128 Suppl 1:9-17. doi: 10.1111/bju.15365. Epub 2021 May 6. BJU Int. 2021. PMID: 33960102
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
Connolly EA, Weickhardt A, Grimison P, Asher R, Heller GZ, Lewin J, Liow E, Toner G, Tung ILY, Tran B, Hill S, Walpole E, McKenzie J, Kuchel A, Goh J, Forgeson G, Tan A, Joshi A, Wickham A, Tan H, Wang Y, Winstanley MA, Hamad N, Wong V. Connolly EA, et al. BJU Int. 2022 Jun;130 Suppl 1:5-16. doi: 10.1111/bju.15648. Epub 2022 Mar 31. BJU Int. 2022. PMID: 35355402 Review.
Treatment de-escalation for stage II seminoma.
Wood GE, Chamberlain F, Tran B, Conduit C, Liow E, Nicol DL, Shamash J, Alifrangis C, Rajan P. Wood GE, et al. Nat Rev Urol. 2023 Aug;20(8):502-512. doi: 10.1038/s41585-023-00727-0. Epub 2023 Mar 7. Nat Rev Urol. 2023. PMID: 36882564 Review.
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T, Pal SK, De Velasco G, Hansen AR, Beuselinck B, Kollmannsberger CK, Powles T, McGregor BA, Duh MS, Huynh L, Heng DYC. Wells JC, et al. Clin Genitourin Cancer. 2021 Aug;19(4):354-361. doi: 10.1016/j.clgc.2021.03.006. Epub 2021 Mar 17. Clin Genitourin Cancer. 2021. PMID: 33863648 Free article.
17 results